<DOC>
	<DOCNO>NCT01709656</DOCNO>
	<brief_summary>The investigator recruit active ankylose spondylitis patient injection treatment Human Mesenchymal Stem Cells ( prospective , open-label , masculine medicine control ( NSAIDs ) , clinical trial ) , collect Peripheral Blood Lymphocyte ( PBMCs ) serum treatment 24 week test gene expression profile study related pathogenesis AS</brief_summary>
	<brief_title>A Molecule Basic Study Early Warning New Pathogenic Risk Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>1 . Aged 1665 year , sign Informed Consent 2 . Fulfill 1984 modified NewYork classification criterion AS 3 . Have active refractory disease define score ≥40 Bath AS Disease Activity Index ( BASDAI ) ( 0100 ) despite optimal nonsteroidal antiinflammatory drug ( NSAID ) treatment . 4 . Commitment contraceptive woman 1 . Completely stiff spine 2 . Received spinal joint surgery within 2 month 3 . Received antiTNF therapy within 3 month 4 . History listed disease : heart failure , Multiple sclerosis , severe chronic obstructive pulmonary disease , frequent infection , lymphoma cancer , tuberculosis 5 . Female pregnancy breast feeding 6 . Hb≤ 9g/dl male Hb ≤ 8.5 g/dl male , ALT/AST≥2folds upper level normal range , Creatine≥120mol/L ( ≤1.4mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>